Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s share price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $211.01 and traded as high as $214.26. Genmab A/S shares last traded at $207.54, with a volume of 859 shares.
Genmab A/S Stock Performance
The stock’s fifty day moving average is $210.66 and its two-hundred day moving average is $237.25. The firm has a market cap of $13.74 billion, a price-to-earnings ratio of 19.99 and a beta of 1.04.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
- Five stocks we like better than Genmab A/S
- The Role Economic Reports Play in a Successful Investment Strategy
- Bloom Energy: Powering the Future With Decentralized Energy
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Options Trading – Understanding Strike Price
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
